Lanatoside CCAS# 17575-22-3 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 17575-22-3 | SDF | Download SDF |
| PubChem ID | 3879 | Appearance | White powder |
| Formula | C49H76O20 | M.Wt | 985.1 |
| Type of Compound | Steroids | Storage | Desiccate at -20°C |
| Synonyms | Digilanide C; Digilanogen C; Isolanide; Lanatigen C | ||
| Solubility | DMSO : 50 mg/mL (50.76 mM; Need ultrasonic) Ethanol : 2 mg/mL (2.03 mM; Need ultrasonic) | ||
| Chemical Name | [6-[6-[6-[[12,14-dihydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-4-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2-methyloxan-3-yl]oxy-2-methyl-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-4-yl] acetate | ||
| SMILES | CC1C(C(CC(O1)OC2CCC3(C(C2)CCC4C3CC(C5(C4(CCC5C6=CC(=O)OC6)O)C)O)C)O)OC7CC(C(C(O7)C)OC8CC(C(C(O8)C)OC9C(C(C(C(O9)CO)O)O)O)OC(=O)C)O | ||
| Standard InChIKey | JAYAGJDXJIDEKI-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C49H76O20/c1-21-43(67-38-17-32(53)44(22(2)62-38)68-39-18-33(64-24(4)51)45(23(3)63-39)69-46-42(58)41(57)40(56)34(19-50)66-46)31(52)16-37(61-21)65-27-9-11-47(5)26(14-27)7-8-29-30(47)15-35(54)48(6)28(10-12-49(29,48)59)25-13-36(55)60-20-25/h13,21-23,26-35,37-46,50,52-54,56-59H,7-12,14-20H2,1-6H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Lanatoside C, a cardiac glycoside, is an anti-arrhythmic agent. 2. Lanatoside C acts through protein kinase Cδ to cause apoptosis of human hepatocellular carcinoma cells. 3. Lanatoside C can effectively inhibit all four serotypes of dengue virus, flavivirus Kunjin, alphavirus Chikungunya and Sindbis virus as well as the human enterovirus 71, suggest that lanatoside C possesses broad spectrum antiviral activity against several groups of positive-sense RNA viruses. |
| Targets | Akt | mTOR | PKC | Antifection |
Lanatoside C Dilution Calculator
Lanatoside C Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.0151 mL | 5.0756 mL | 10.1513 mL | 20.3025 mL | 25.3781 mL |
| 5 mM | 0.203 mL | 1.0151 mL | 2.0303 mL | 4.0605 mL | 5.0756 mL |
| 10 mM | 0.1015 mL | 0.5076 mL | 1.0151 mL | 2.0303 mL | 2.5378 mL |
| 50 mM | 0.0203 mL | 0.1015 mL | 0.203 mL | 0.4061 mL | 0.5076 mL |
| 100 mM | 0.0102 mL | 0.0508 mL | 0.1015 mL | 0.203 mL | 0.2538 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Lanatoside C is a cardiac glycoside, can be used in the treatment of congestive heart failure and cardiac arrhythmia.Lanatoside C has an IC50 of 0.19 μM for dengue virus infection in HuH-7 cells. Target: in vitro: Dose-dependent reduction in dengue viral RNA and viral proteins synthesis were also observed upon treatment with increasing concentrations of Lanatoside C. Time of addition study indicated that Lanatoside C inhibits the early processes of the dengue virus replication cycle. Furthermore, Lanatoside C can effectively inhibit all four serotypes of dengue virus, flavivirus Kunjin, alphavirus Chikungunya and Sindbis virus as well as the human enterovirus 71. Lanatoside C possesses broad spectrum antiviral activity against several groups of positive-sense RNA viruses. [2]
References:
[1]. Crommentuijn MH, et al. Intracranial AAV-sTRAIL combined with lanatoside C prolongs survival in an orthotopic xenograft mouse model of invasive glioblastoma. Mol Oncol. 2015 Dec 11. pii: S1574-7891(15)00226-4.
[2]. Cheung YY, et al. Antiviral activity of lanatoside C against dengue virus infection. Antiviral Res. 2014 Nov;111:93-99.
- Lanatoside B
Catalog No.:BCN6544
CAS No.:17575-21-2
- α-Conotoxin MII
Catalog No.:BCC5743
CAS No.:175735-93-0
- Tapentadol Hydrochloride
Catalog No.:BCC9159
CAS No.:175591-09-0
- Longifloroside A
Catalog No.:BCN1123
CAS No.:175556-08-8
- Voreloxin Hydrochloride
Catalog No.:BCC2045
CAS No.:175519-16-1
- Fmoc-Phe(4-Cl)-OH
Catalog No.:BCC3173
CAS No.:175453-08-4
- Fmoc-3-Pal-OH
Catalog No.:BCC2653
CAS No.:175453-07-3
- Eriosematin A
Catalog No.:BCN3465
CAS No.:175448-02-9
- Z-Phe(4-F)-OH
Catalog No.:BCC3221
CAS No.:17543-58-7
- Voreloxin
Catalog No.:BCC2044
CAS No.:175414-77-4
- S 18986
Catalog No.:BCC6081
CAS No.:175340-20-2
- Fmoc-Thr(HPO3Bzl)-OH
Catalog No.:BCC3551
CAS No.:175291-56-2
- PPAHV
Catalog No.:BCC7077
CAS No.:175796-50-6
- H-Dab.HBr
Catalog No.:BCC3184
CAS No.:1758-80-1
- Wedelialactone A
Catalog No.:BCN6733
CAS No.:175862-40-5
- Valganciclovir HCl
Catalog No.:BCC4745
CAS No.:175865-59-5
- (±)-Sigmoidin A
Catalog No.:BCN3372
CAS No.:176046-04-1
- Fucosterol
Catalog No.:BCN6427
CAS No.:17605-67-3
- Zerumin A
Catalog No.:BCN3684
CAS No.:176050-48-9
- H-Val-OEt.HCl
Catalog No.:BCC3141
CAS No.:17609-47-1
- Maribavir
Catalog No.:BCC5259
CAS No.:176161-24-3
- Depressine
Catalog No.:BCN7851
CAS No.:176182-06-2
- LY 354740
Catalog No.:BCC7614
CAS No.:176199-48-7
- Nervogenic acid
Catalog No.:BCN1124
CAS No.:17622-86-5
Lanatoside C sensitizes glioblastoma cells to tumor necrosis factor-related apoptosis-inducing ligand and induces an alternative cell death pathway.[Pubmed:21757445]
Neuro Oncol. 2011 Nov;13(11):1213-24.
Human glioblastoma (GBM) cells are notorious for their resistance to apoptosis-inducing therapeutics. We have identified Lanatoside C as a sensitizer of GBM cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced cell death partly by upregulation of the death receptor 5. We show that Lanatoside C sensitizes GBM cells to TRAIL-induced apoptosis in a GBM xenograft model in vivo. Lanatoside C on its own serves as a therapeutic agent against GBM by activating a caspase-independent cell death pathway. Cells treated with Lanatoside C showed necrotic cell morphology with absence of caspase activation, low mitochondrial membrane potential, and early intracellular ATP depletion. In conclusion, Lanatoside C sensitizes GBM cells to TRAIL-induced cell death and mitigates apoptosis resistance of glioblastoma cells by inducing an alternative cell death pathway. To our knowledge, this is one of the first examples of use of caspase-independent cell death inducers to trigger tumor regression in vivo. Activation of such mechanism may be a useful strategy to counter resistance of cancer cells to apoptosis.
Antiviral activity of lanatoside C against dengue virus infection.[Pubmed:25251726]
Antiviral Res. 2014 Nov;111:93-9.
Dengue infection poses a serious threat globally due to its recent rapid spread and rise in incidence. Currently, there is no approved vaccine or effective antiviral drug for dengue virus infection. In response to the urgent need for the development of an effective antiviral for dengue virus, the US Drug Collection library was screened in this study to identify compounds with anti-dengue activities. Lanatoside C, an FDA approved cardiac glycoside was identified as a candidate anti-dengue compound. Our data revealed that Lanatoside C has an IC50 of 0.19muM for dengue virus infection in HuH-7 cells. Dose-dependent reduction in dengue viral RNA and viral proteins synthesis were also observed upon treatment with increasing concentrations of Lanatoside C. Time of addition study indicated that Lanatoside C inhibits the early processes of the dengue virus replication cycle. Furthermore, Lanatoside C can effectively inhibit all four serotypes of dengue virus, flavivirus Kunjin, alphavirus Chikungunya and Sindbis virus as well as the human enterovirus 71. These findings suggest that Lanatoside C possesses broad spectrum antiviral activity against several groups of positive-sense RNA viruses.
Lanatoside C, a cardiac glycoside, acts through protein kinase Cdelta to cause apoptosis of human hepatocellular carcinoma cells.[Pubmed:28387249]
Sci Rep. 2017 Apr 7;7:46134.
Recent studies have revealed that cardiac glycosides, such as digitalis and digoxin, have anticancer activity and may serve as lead compounds for the development of cancer treatments. The poor prognosis of hepatocellular carcinoma (HCC) patients reflects the development of resistance to current chemotherapeutic agents, highlighting the need for discovering new small-molecule therapeutics. Here, we found that Lanatoside C, an anti-arrhythmic agent extracted from Digitalis lanata, inhibited the growth of HCC cells and dramatically decreased tumor volume as well as delayed tumor growth without obvious body weight loss. Moreover, Lanatoside C triggered mitochondrial membrane potential (MMP) loss, activation of caspases and translocation of apoptosis-inducing factor (AIF) into the nucleus, which suggests that Lanatoside C induced apoptosis through both caspase-dependent and -independent pathways. Furthermore, we discovered that Lanatoside C activated protein kinase delta (PKCdelta) via Thr505 phosphorylation and subsequent membrane translocation. Inhibition of PKCdelta reversed Lanatoside C-induced MMP loss and apoptosis, confirming that Lanatoside C caused apoptosis through PKCdelta activation. We also found that the AKT/mTOR pathway was negatively regulated by Lanatoside C through PKCdelta activation. In conclusion, we provide the first demonstration that the anticancer effects of Lanatoside C are mainly attributable to PKCdelta activation.
